<?xml version="1.0" encoding="UTF-8"?>
<p id="p0095">Several reports of clinical trials currently underway, but not yet peer-reviewed, have claimed that convalescent plasma from recovered patients displays neutralizing activity, which could be transferred to recipients by plasma infusion (
 <xref rid="bib51" ref-type="bibr">Shen etÂ al., 2020</xref>). In addition, monoclonal antibodies against the receptor-binding domain of the spike protein derived from convalescent patients have displayed neutralizing activity in a pseudovirus model and also protected against reinfection in animal models after recovery and re-challenge (
 <xref rid="bib1" ref-type="bibr">Bao et al., 2020</xref>; 
 <xref rid="bib23" ref-type="bibr">Ju et al., 2020</xref>).
</p>
